Supernus Pharmaceuticals Inc (SUPN) valuation
Supernus Pharmaceuticals P/E ratio history
Supernus Pharmaceuticals has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 8 fiscal year ends its P/E ranged from 10.7 (year to Dec 2020) to 37.6 (year to Dec 2017), with a median of 21.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $49.70 | -$0.68 | n/m | 14.5 |
| Dec 31, 2024 | $36.16 | $1.32 | 27.4 | 17.0 |
| Dec 31, 2023 | $28.94 | $0.02 | n/m | 15.6 |
| Dec 31, 2022 | $35.67 | $1.04 | 34.3 | 32.7 |
| Dec 31, 2021 | $29.16 | $0.98 | 29.8 | — |
| Dec 31, 2020 | $25.16 | $2.36 | 10.7 | — |
| Dec 31, 2019 | $23.72 | $2.11 | 11.2 | — |
| Dec 31, 2018 | $33.22 | $2.06 | 16.1 | — |
| Dec 31, 2017 | $39.85 | $1.06 | 37.6 | — |
| Dec 31, 2016 | $25.25 | $1.70 | 14.9 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Supernus Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Supernus PharmaceuticalsSUPN | $2.43B | — | 10.9 | 2.9 |
| Pediatrix Medical GroupMD | $2.42B | 16.2 | 12.3 | 1.2 |
| PrecigenPGEN | $2.47B | — | 16.6 | 28.9 |
| Brookdale Senior LivingBKD | $2.48B | — | — | 0.8 |
| Celldex TherapeuticsCLDX | $2.36B | — | — | — |
| Clover Health Investments Corp ClaCLOV | $2.35B | — | 30.8 | 1.0 |
| Addus HomecareADUS | $2.34B | 22.0 | 17.2 | 1.6 |
| Viridian Therapeutics OrsVRDN | $2.54B | — | — | 35.8 |
| Prestige Consumer HealthcarePBH | $2.32B | 13.7 | 10.4 | 2.1 |
| Peer median | 16.2 | 16.6 | 1.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: SUPN financials · SUPN returns
No forecast, no recommendation. This page describes Supernus Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.